Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

Background The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery
needs to be estimated when considering adjuvant systemic therapy. We assessed …

Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …

Accurate risk stratification of gastrointestinal stromal tumors (GISTs) has become
increasingly important owing to emerging adjuvant systemic treatments. All GISTs have …

Background Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …

Purpose Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI
stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is …

Background This study assessed the outcomes of patients with a gastrointestinal stromal
tumour (GIST) that ruptured before or during resection. Methods The records of 23 patients …

Gastrointestinal stromal tumor has received a lot of attention over the last 10 years due to its
unique biologic behavior, clinicopathological features, molecular mechanisms, and …

BACKGROUND: Approval of imatinib for adjuvant treatment of gastrointestinal stromal
tumours (GIST) raised discussion about accuracy of prognostic factors in GIST and the …

Gastrointestinal stromal tumors (GISTs) are rare life-threatening forms of cancer that may
arise anywhere in the GI tract. Herein, we aimed to review the literature to describe the …